GeneDesign opens large-scale production facility in Osaka

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/gorodenkoff)
(Image: Getty/gorodenkoff)

Related tags: Ajinomoto Bio-Pharma, GeneDesign, Japan

The Ajinomoto subsidiary opens a development and production base for oligonucleotide drug substances in Japan.

GeneDesign, Japanese contract development and manufacturing organization (CDMO), held the grand opening of the facility in Osaka, Japan, on April 5, prior to CPhI North America. The 2,000m² building will improve the company’s production capacity.

GeneDesign, a nucleic acid drug manufacturer who provides custom oligonucleotides for the biopharmaceutical industry, was acquired​ by Ajinomoto in 2016.

As stated by Ajinomoto, the facility “will provide a Class 100,000 clean area for cGMP manufacturing of oligonucleotide APIs, a multipurpose room to custom synthesize heavily modified oligonucleotides, and the world's largest solid phase oligonucleotide synthesizer, OligoProcess, the first of this type of machine to be installed in Japan​”.

The development center also houses process development labs to support manufacturing activities and R&D labs for the development of novel oligonucleotide manufacturing technologies.

At the same time as the production facility opening, Ajinomoto announced the integration of the two companies, stating GeneDesign has now joined the global organization.

The investment in its subsidiary’s facility is part of broader investment plan, with Ajinomoto recently announcing an investment​ of $100m (€88m) to expand its facilities in Belgium and the US.

Related news

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars